Geoffery Burnstock's influence on the evolution of P2X3 receptor pharmacology.
作者信息
Jarvis Michael F
机构信息
Global Medical Affairs, Abbvie, Inc., 1 N Waukegan Rd., North Chicago, IL, 60064, USA.
出版信息
Purinergic Signal. 2021 Mar;17(1):33-39. doi: 10.1007/s11302-020-09744-9. Epub 2020 Oct 8.
Abstract
摘要
相似文献
1
Geoffery Burnstock's influence on the evolution of P2X3 receptor pharmacology.
Purinergic Signal. 2021 Mar;17(1):33-39. doi: 10.1007/s11302-020-09744-9. Epub 2020 Oct 8.
2
Potentiation of the P2X3 ATP receptor by PAR-2 in rat dorsal root ganglia neurons, through protein kinase-dependent mechanisms, contributes to inflammatory pain.
Eur J Neurosci. 2012 Aug;36(3):2293-301. doi: 10.1111/j.1460-9568.2012.08142.x. Epub 2012 May 23.
3
A317491 relieved HIV gp120-associated neuropathic pain involved in P2X receptor in dorsal root ganglia.
Brain Res Bull. 2017 Apr;130:81-89. doi: 10.1016/j.brainresbull.2017.01.002. Epub 2017 Jan 5.
4
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives.
Bioorg Med Chem Lett. 2020 Dec 15;30(24):127636. doi: 10.1016/j.bmcl.2020.127636. Epub 2020 Oct 22.
5
[P2x3-receptor desensitization as an alternative mechanism of analgesia].
Fiziol Zh (1994). 2013;59(2):104-10.
6
P2X3 and P2X2/3 receptors activation induces articular hyperalgesia by an indirect sensitization of the primary afferent nociceptor in the rats' knee joint.
Eur J Pharmacol. 2020 Jul 15;879:173054. doi: 10.1016/j.ejphar.2020.173054. Epub 2020 Mar 4.
7
Activation of P2X3 receptors in the cerebrospinal fluid-contacting nucleus neurons reduces formalin-induced pain behavior via PAG in a rat model.
Neuroscience. 2017 Sep 1;358:93-102. doi: 10.1016/j.neuroscience.2017.06.036. Epub 2017 Jun 30.
8
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
Expert Opin Ther Pat. 2019 Dec;29(12):943-963. doi: 10.1080/13543776.2019.1693542. Epub 2019 Nov 20.
9
Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.
Neuropharmacology. 2015 Dec;99:115-30. doi: 10.1016/j.neuropharm.2015.07.008. Epub 2015 Jul 13.
10
Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies.
J Biol Chem. 2016 Jun 3;291(23):12254-70. doi: 10.1074/jbc.M116.722330. Epub 2016 Apr 20.
引用本文的文献
1
P2X3 receptors in the paraventricular hypothalamus: a specific target for visceral pain.
Purinergic Signal. 2025 Jun 20. doi: 10.1007/s11302-025-10099-2.
2
ATP, an attractive target for the treatment of refractory chronic cough.
Purinergic Signal. 2022 Sep;18(3):289-305. doi: 10.1007/s11302-022-09877-z. Epub 2022 Jun 21.
3
Mechanisms of ATP release in pain: role of pannexin and connexin channels.
Purinergic Signal. 2021 Dec;17(4):549-561. doi: 10.1007/s11302-021-09822-6. Epub 2021 Nov 18.
4
P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications.
Front Pharmacol. 2021 Apr 13;12:653561. doi: 10.3389/fphar.2021.653561. eCollection 2021.
5
Purines in Pain as a Gliopathy.
Front Pharmacol. 2021 Mar 10;12:649807. doi: 10.3389/fphar.2021.649807. eCollection 2021.
6
That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes.
Purinergic Signal. 2021 Mar;17(1):9-23. doi: 10.1007/s11302-021-09763-0. Epub 2021 Feb 1.
7
Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Biochem Pharmacol. 2021 May;187:114311. doi: 10.1016/j.bcp.2020.114311. Epub 2020 Oct 29.
本文引用的文献
1
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.
2
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
Expert Opin Ther Pat. 2019 Dec;29(12):943-963. doi: 10.1080/13543776.2019.1693542. Epub 2019 Nov 20.
3
Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.
Br J Pharmacol. 2019 Jul;176(13):2279-2291. doi: 10.1111/bph.14677. Epub 2019 May 11.
4
BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Pulm Pharmacol Ther. 2019 Jun;56:56-62. doi: 10.1016/j.pupt.2019.03.007. Epub 2019 Mar 20.
5
P2X receptor channels in chronic pain pathways.
Br J Pharmacol. 2018 Jun;175(12):2219-2230. doi: 10.1111/bph.13957. Epub 2017 Aug 17.
6
X-ray structures define human P2X(3) receptor gating cycle and antagonist action.
Nature. 2016 Oct 6;538(7623):66-71. doi: 10.1038/nature19367. Epub 2016 Sep 14.
7
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
Lancet. 2015 Mar 28;385(9974):1198-205. doi: 10.1016/S0140-6736(14)61255-1. Epub 2014 Nov 25.
8
Characterization of P1 (adenosine) purinoceptors.
Curr Protoc Pharmacol. 2013 Oct 8;62:1.9.1-1.9.16. doi: 10.1002/0471141755.ph0109s62.
9
The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.
Front Cell Neurosci. 2013 Dec 19;7:267. doi: 10.3389/fncel.2013.00267.
10
P2X receptors as drug targets.
Mol Pharmacol. 2013 Apr;83(4):759-69. doi: 10.1124/mol.112.083758. Epub 2012 Dec 19.
Zotero 插件